Protective effects of Vitamin E on endocrine disruptors, PCB-induced dopaminergic neurotoxicity.
The protective effect of an antioxidant, Vitamin E (dl-alpha-tocopherol, 100 mg/kg/day, 8 days p.o. in vivo and 10 and 50 microM in vitro) was tested against PCB-induced neurotoxicity.


METHODS
Microdialysis was used to investigate changes in the striatal extracellular dopamine level and in p-nNOS expression in PCB-treated (Aroclor 1254, 10 microg/ml, 2 microl/min, 5 h; 6 microg was infused by microdialysis probe) rats.


METHODS
Cell viability and levels of p-nNOS expression were observed in PCB-treated (Aroclor 1254, 5 microg/ml) immortalized dopaminergic cell line (CATH.a cells).


RESULTS
Treatment with PCB: (1) decreased the extracellular dopamine level in rat striatum, (2) increased p-nNOS expression both in rat striatal tissue and in CATH.a cells, (3) reduced the cell viability of, and (4) increased LDH release by CATH.a cells. However, Vitamin E showed a protective effect against PCB-induced toxicity and downregulation of the extracellular dopamine level. These results indicate that Vitamin E may have neuroprotective effects by inhibiting PCB-induced nNOS phosphorylation.
Yun
Jae Suk
JS
Division of General Pharmacology, National Institute of Toxicological Research, Korea Food and Drug Administration, 5 Nokbundong, Eunpyung-Gu, Seoul 122-704, South Korea.
Na
Han Kwang
HK
Park
Ki-Sook
KS
Lee
Yun Hee
YH
Kim
Eun Yeob
EY
Lee
Sung Yong
SY
Kim
Joo-Il
JI
Kang
Ju-Hee
JH
Kim
Dong Sup
DS
Choi
Ki Hwan
KH
D000284:Administration, Oral; D000818:Animals; D018929:Cell Culture Techniques; D002470:Cell Survival / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D052244:Endocrine Disruptors; D015151:Immunoblotting; D008297:Male; D017551:Microdialysis; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D052248:Nitric Oxide Synthase Type I / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D011078:Polychlorinated Biphenyls / Q000037:antagonists & inhibitors / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects; D014810:Vitamin E / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D052244:Endocrine Disruptors; D014810:Vitamin E; D011078:Polychlorinated Biphenyls; D052248:Nitric Oxide Synthase Type I; D004298:Dopamine